Mindray dazzled EA23 with innovative OR & ICU Solutions

From 3-5 June, Mindray showcased its innovative OR & ICU solutions at the Euroanaesthesia 2023 Congress (EA23) in Glasgow, with the theme “Innovate to empower the Anaesthesia Future”. This year, Mindray brought pioneering OR solutions that address three major medical scenarios, based on their flagship A-Series anesthesia systems. In addition, Mindray also presented an advanced ICU solution that garnered significant attention. Mindray’s impressive display cemented its leading role in the industry and left the audience eager to see what’s next.

One of Mindray’s highlights was unveiling the new A-Series anesthesia systems, which is an upgraded version of the old A5 and A7 Anesthesia Machines. It features various functions and devices that increase anaesthetic efficiency while maintaining all-round safety. The A-Series anesthesia systems have received high anticipation from the audience and are expected to be launched officially soon.

Furthermore, Mindray announced a new milestone in the strategic partnership with Edwards Lifesciences in Europe by unveiling an integrated FloTrac interface solution in Mindray’s flagship BeneVision N series patient monitoring system. This integration enhances the N series monitor’s capability and flexibility to monitor the hemodynamic status, enabling clinicians to proactively prevent patient deterioration and apply individualized fluid management.

During the on-site guided tour and workshop, Mindray’s integrated technology of ultrasound and anesthesia systems left a positive impression on the audience. The technology significantly improved the efficiency of anesthetic puncture during operations, demonstrating Mindray’s commitment to optimizing clinical workflow for medical professionals.

In addition to its focus on product innovation, Mindray also works closely with leading experts, academic institutions and medical centers globally to foster knowledge exchange and drive new discoveries in the field of medical technology. These collaborations help to keep Mindray at the forefront of the healthcare industry.

Recently, the Annals of Intensive Care published a study entitled “Preoxygenation with Standard Facemask Combining Apnoeic Oxygenation Using High-Flow Nasal Cannula versus Standard Facemask Alone in Patients with and without Obesity: The OPTIMASK International Study”. It is an international research supported by Mindray, jointly with world-leading experts from four countries, marking a milestone in Mindray’s academic research on anesthesia.

Mindray not only provides innovative medical solutions but also fosters knowledge sharing and collaboration within the global medical community. Prior to the EA23 in Glasgow, Mindray hosted Mindray Day – an educational program tailored for anesthesiologists and ICU doctors. The program featured simulation training based on real clinical scenarios in OR and ICU, and academic sessions on a variety of topics of great interest to medical professionals globally, including oxygenation delivery, lung protection, mechanical ventilation for ARDS, HFJV, and more. This initiative reflects Mindray’s ongoing commitment to creating opportunities for exchanging insights and sharing new ideas within the industry.

Mindray’s impressive performance at EA23 is a testament to the company’s strong product development capabilities, commitment to innovation, and outstanding academic achievements.

As a leading medical device manufacturer, Mindray is dedicated to improving healthcare outcomes worldwide by providing cutting-edge technologies and valuable insights to medical professionals. By empowering healthcare providers with innovative solutions and enhancing access to quality care, Mindray is setting a high standard in the industry and inspiring others to follow suit. With its unwavering focus on bringing better healthcare to all, Mindray is poised to make significant contributions to the global healthcare landscape.
MB Bureau